Exact Sciences rallies 27% on bullish outlook for colorectal cancer liquid biopsy test

Exact Sciences (EXAS +27.2%), the developer of a molecular screening test for colorectal cancer (CRC) called Cologuard, jumps on an 8x surge in volume in apparent response to comments by CEO Kevin Conroy at the Cowen Liquid Biopsy Summit that that early data on its blood test for CRC are promising. Mr. Conroy said, “We will bring the best CRC blood test to physicians and patients though we don’t believe the blood test will replace colonoscopy or Cologuard.”

Liquid biopsies, measuring circulating pieces of DNA in peripheral blood that are shed from cancer cells, have been on the commercial horizon for some years now but appear to gaining momentum. Recently, genetic testing gear maker Illumina (ILMN +3.4%) agreed to pay $8B in cash and stock to acquire liquid biopsy spinout GRAIL.


READ  Shares in Ted Baker surge by more than 13 per cent after its exiled founder considers a buyout


Please enter your comment!
Please enter your name here